Idexx Laboratories (IDXX) Accumulated Expenses (2009 - 2026)

Idexx Laboratories (IDXX) has reported Accumulated Expenses for 18 consecutive years, with $453.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 7.57% year-over-year to $453.6 million; the TTM figure through Mar 2026 stood at $453.6 million (down 7.57% YoY), while the FY2025 annual figure was $530.1 million, up 5.58% from the prior year.
• Accumulated Expenses came in at $453.6 million for Q1 2026 at Idexx Laboratories, down from $530.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $541.1 million in Q2 2024, with the low at $387.5 million in Q2 2022.
• Average Accumulated Expenses over 5 years is $455.9 million, with a median of $453.6 million recorded in 2026.
• Across the five-year window, Accumulated Expenses soared 35.48% in 2024 and decreased 22.94% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $433.7 million in 2022, then grew by 10.39% to $478.7 million in 2023, then increased by 4.89% to $502.1 million in 2024, then grew by 5.58% to $530.1 million in 2025, then fell by 14.45% to $453.6 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $453.6 million, $530.1 million, and $488.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.